Small molecule drug developer Aria Pharmaceuticals (Palo Alto, Calif.) has announced that two investigational treatments for idiopathic pulmonary fibrosis (IPF), TXR-1002 and TXR-1007, demonstrated efficacy and tolerability in preclinical research.

Read more here.